Trial Profile

Effectiveness and Persistence of Therapy With GLP-1 Receptor Agonists in Clinical Practice. A Multicenter Retrospective Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dulaglutide (Primary) ; Exenatide (Primary) ; Insulin degludec (Primary) ; Insulin degludec/liraglutide (Primary) ; Insulin glargine (Primary) ; Insulin-glargine/lixisenatide (Primary) ; Liraglutide (Primary) ; Lixisenatide (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms GLP-1REWIN

Most Recent Events

01 Mar 2021 Status changed from active, no longer recruiting to completed.
24 Apr 2020 New trial record
17 Apr 2020 Results assessing effectiveness of dulaglutide on on HbA1c and body weight reduction in a real-world setting, published in the Journal of Clinical Endocrinology and Metabolism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com